ZLDPF Zealand Pharma A/S

Zealand Pharma convenes its Annual General Meeting 2025

Zealand Pharma convenes its Annual General Meeting 2025

Company Announcement – No. 3 / 2025

Zealand Pharma convenes its Annual General Meeting 2025

Notice to convene the Annual General Meeting 2025 of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company").

The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on:

Thursday, March 27, 2025 at 3:00 pm (CET)

The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in person (hybrid meeting).

The Annual General Meeting will be held electronically via the virtual portal hosted by Computershare A/S, and physically at the Company's registered address Sydmarken 11, DK-2860 Søborg.

Please find further information in the accompanying attachment.

Attachment



EN
20/02/2025

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

BC-bc user ... (+8)
  • BC-bc user
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Lynn Hautekeete
  • Michiel Declercq
  • Wim Lewi
COMB Compagnie du Bo...
JEN JENSEN-GROUP ... (+9)

Morning Notes : ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, H...

: ATEB BB, COMB BB, BPOST BB, ELI BB, GLPG NA, JEN BB, HYSG BB, ZEAL DC, ECMPA NA

COMB COMPAGNIE DU BOIS SAUVAGE SA
JEN JENSEN-GROUP
ELI ELIA GROUP SA/NV
ZLDPF ZEALAND PHARMA A/S
BPOST BPOST SA
ATEB ATENOR S.A.
GLOG GLOBAL GRAPHICS S.A.
GLPG GALAPAGOS NV
ECMPA EUROCOMMERCIAL PROPERTIES NV
03/06/26 March 6, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Petrelintide shows modest weight loss but excellent tol...

Zealand reported mixed results from the phase 2 (ZUPREME-1) trial of petrelintide in overweight/obesity, showing a modest 10.7% weight loss at 42 weeks, while demonstrating excellent tolerability. We think this outcome makes first line positioning difficult, and view petrelintide as better suited for weight loss maintenance (subject to positive data in that setting). We adjust our peak sales estimate to $ 7b (from $ 22b), which brings down our TP to DKK 500 (from DKK 960). Given the lower upside...

ZLDPF ZEALAND PHARMA A/S
03/06/26 March 6, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma announces positive Phase 2 results for petrelintide, an...

Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Company announcement – No. 3 / 2026 Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity Petrelintide achieved up to 10.7% mean body weight reduction at week 42 (versus 1.7% with placebo) and demonstrated placebo-like tolerabilityAt the maximally effective dose, the...

March 5, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma convenes its Annual General Meeting 2026

Zealand Pharma convenes its Annual General Meeting 2026 Company announcement – No. 2 / 2026 Zealand Pharma convenes its Annual General Meeting 2026 Copenhagen, Denmark, February 19, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby convenes its Annual General Meeting 2026. The Board of Directors of Zealand Pharma A/S hereby convenes the Annual General Meeting of the Company to be held on: Thursday, 26 March 2026 at 03:00 PM (CET) / 9:00 (ET) The Annual General Meet...

February 19, 2026 1 EN
Mathijs Geerts Danau
  • Mathijs Geerts Danau
ZLDPF Zealand Pharma ...

Zealand Pharma FY25 results: Looking forward to petrelintide phase 2 d...

Zealand reported FY25 results, ending the year with cash of DKK 15,109m (YE24: DKK 9,022m), reinforcing the strong balance sheet. OPEX increased to DKK 2,101m (FY24: 1,324m) driven by increased R&D spending related to the ongoing petrelintide phase 2 trials. For FY26, Zealand guides OPEX of DKK 2,700-3,300m, due to continued investment in the petrelintide franchise. We look forward to the read-out of the petrelintide phase 2 trial in obesity expected in 1Q26, which could confirm petrelintide's p...

ZLDPF ZEALAND PHARMA A/S
02/19/26 February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch